drugset / Trial / NCT05281341

Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI)

NCT05281341

Phase 4 Completed 160 enrolled Alexandria University
RandomizedParallel-groupOpen-labelTreatment

Summary

Despite the use of various treatment strategies, poor response to ovarian stimulation remains a major clinical challenge with lower chance to obtain sufficient number of oocytes and thus less likely to conceive with high risk of cycle cancellation. The aim of this study is to evaluate the effect of recombinant human GH administration to gonadotropins on clinical and laboratory ICSI outcomes in expected poor responders more and less than 35 years (Poseidon group 4 and 3 respectively).

Timeline

Start
2020-01-13
Primary completion
2021-12-10
Completion
2022-02-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 4 iu Subcutaneous

Indications